Shilpa Medicare's Unit VI, Bengaluru facility has been issued UK MHRA Good Manufacturing Practice certification; Stock soars 3%

13 Jul 2022 , 09:16 AM

Shilpa Medicare Limited has informed that the Company’s newly commissioned facility for manufacturinf and testing of Orodispersible films and Transdermal systems situated at Dabaspet, Bengaluru, Karnataka State, has been issued GMP Certificate by UK MHRA.

The facility was inspected by MHRA from April18, 2022 to April 20, 2022.

In a regulatory filing, the company sid, “The facility has capabilities of manufacturing and testing specialized dosage forms like Orodispersible Films and Transdermal systems. It is backed up with strong Research and Development of challenging orodispersible films and transdermal technologies. The GMP facility is equipped with state of art infrastructure to meet commercial requirements from a global perspective.”

On Wednesday early morning trade, Shilpa Medicare was trading at Rs411.05 per share up by Rs12.95 or 3.25% from its previous closing of Rs398.10 per share on the BSE.